Publication:
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

dc.contributor.authorHofstra, L Marije
dc.contributor.authorSauvageot, Nicolas
dc.contributor.authorAlbert, Jan
dc.contributor.authorAlexiev, Ivailo
dc.contributor.authorGarcia, Federico
dc.contributor.authorStruck, Daniel
dc.contributor.authorVan de Vijver, David A M C
dc.contributor.authorÅsjö, Birgitta
dc.contributor.authorBeshkov, Danail
dc.contributor.authorCoughlan, Suzie
dc.contributor.authorDescamps, Diane
dc.contributor.authorGriskevicius, Algirdas
dc.contributor.authorHamouda, Osamah
dc.contributor.authorHorban, Andrzej
dc.contributor.authorVan Kasteren, Marjo
dc.contributor.authorKolupajeva, Tatjana
dc.contributor.authorKostrikis, Leondios G
dc.contributor.authorLiitsola, Kirsi
dc.contributor.authorLinka, Marek
dc.contributor.authorMor, Orna
dc.contributor.authorNielsen, Claus
dc.contributor.authorOtelea, Dan
dc.contributor.authorParaskevis, Dimitrios
dc.contributor.authorParedes, Roger
dc.contributor.authorPoljak, Mario
dc.contributor.authorPuchhammer-Stöckl, Elisabeth
dc.contributor.authorSönnerborg, Anders
dc.contributor.authorStaneková, Danica
dc.contributor.authorStanojevic, Maja
dc.contributor.authorVan Laethem, Kristel
dc.contributor.authorZazzi, Maurizio
dc.contributor.authorZidovec Lepej, Snjezana
dc.contributor.authorBoucher, Charles A B
dc.contributor.authorSchmit, Jean-Claude
dc.contributor.authorWensing, Annemarie M J
dc.contributor.authoraffiliation[Hofstra,LM; Sauvageot,N; Struck,D; Schmit,JC ] Luxembourg Institute of Health, Luxembourg. [Hofstra,LM; Wensing,AMJ] Department of Virology, University Medical Center Utrecht, The Netherlands. [Albert,J; Sönnerborg,A] Karolinska Institute, Solna. Karolinska University Hospital, Stockholm, Sweden. [Alexiev,I; Beshkov,D] National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. [Garcia,F] Complejo Hospitalario Universitario de Granada. Instituto de Investigación IBS Granada, Spain. [Van de Vijver,DAMC; Boucher,CAB] Erasmus MC, University Medical Center, Rotterdam, The Netherlands. [Åsjö,B] University of Bergen, Norway. [Coughlan,S] University College Dublin, Ireland. [Descamps,D] AP-HP Groupe hospitalier Bichat-Claude Bernard. IAME INSERM UMR 1137. Université Paris Diderot Sorbonne Paris Cité, Paris, France. [Griskevicius,A] Lithuanian AIDS Center, Vilnius, Lithuania. [Hamouda,O] Robert Koch Institute, Berlin, Germany. [Horban,A] Hospital of Infectious Diseases, Warsaw, Poland. [Van Kasteren,M] St Elisabeth Hospital, Tilburg, The Netherlands. [Kolupajeva,T] Infectiology Center of Latvia, Riga. [Kostrikis,LG] University of Cyprus, Nicosia. [Liitsola,K] Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland. [Linka,M] National Reference Laboratory for HIV/AIDS, National Institute of Public Health, Prague, Czech Republic. [Mor,O] National HIV Reference Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel. [Nielsen,C] Statens Serum Institut, Copenhagen, Denmark. [Otelea,D] National Institute for Infectious Diseases “Prof. dr. Matei Bals”, Bucharest, Romania. [Paraskevis,D] National Retrovirus Reference Center, University of Athens, Greece. [Paredes,R] IrsiCaixa Foundation, Badalona, Spain. [Poljak,M] Faculty of Medicine, Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia. [Puchhammer-Stöckl,E] Medical University Vienna, Austria. [Staneková,D] Slovak Medical University, Bratislava, Slovakia. [Stanojevic,M] Faculty of Medicine, University of Belgrade, Serbia. [Van Laethem,K] Rega Institute for Medical Research, KU Leuven, Belgium. [Zazzi,M] University of Siena, Italy. [Zidovec Lepej,S] University Hospital for Infectious Diseases “Dr. Fran Mihaljevic”, Zagreb, Croatia.es
dc.contributor.funderThis work was supported by a CORE grant of Fond National de la Recherche Luxembourg (grant number C12/BM/4011111–HIV molecular epidemiology in Europe). This work has been partially supported by the European Commission (fifth framework, grant number QLK2-CT-2001-01344; sixth framework, grant number LSHP-CT-2006-518211, DynaNets grant number 233847; seventh framework, CHAIN grant number 223131); Belgium: Belgian AIDS Reference Laboratory Fund, Belgian Fonds voor Wetenschappelijk Onderzoek (grant number G.0692.14); Cyprus: Cyprus Research Promotion Foundation (grant number Health/0104/22); Denmark: Danish AIDS Foundation; France: Agence Nationale de Recherches sur le SIDA et les Hepatites Virales; Germany: Ministry of Health (grant number 1502-686-18), Ministry of Education and Research (grant number 01KI501); Italy: Fifth National Program on HIV/AIDS, Instituto Superiore di Sanità (grant numbers 40F.56 and 20D.1.6); Luxembourg: Fondation Recherche sur le SiDA and Ministry of Health; Republic of Serbia: Ministry of Education and Science (grant number 175024); Slovakia: project “Center of Excellence of Environmental Health,” ITMS number 26240120033, based on supporting operational research and development program financed from the European Regional Development Fund; and Sweden: Swedish Research Council and Swedish Civil Contingencies Agency.
dc.contributor.groupCohorte de Adultos de la Red de Investigación en SIDA, Spain.es
dc.contributor.groupSPREAD Programes
dc.date.accessioned2016-08-08T07:59:34Z
dc.date.available2016-08-08T07:59:34Z
dc.date.issued2016-03-01
dc.descriptionJournal Article;es
dc.description.abstractBACKGROUND Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. METHODS Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. RESULTS The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. CONCLUSIONS Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.es
dc.description.versionYeses
dc.identifier.citationHofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin. Infect. Dis. 2016; 62(5):655-63es
dc.identifier.doi10.1093/cid/civ963
dc.identifier.essn1537-6591
dc.identifier.issn1058-4838
dc.identifier.pmcPMC4741360
dc.identifier.pmid26620652
dc.identifier.urihttp://hdl.handle.net/10668/2306
dc.journal.titleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.language.isoen
dc.publisherOxford University Presses
dc.relation.publisherversionhttp://cid.oxfordjournals.org/content/62/5/655.abstractes
dc.rights.accessRightsopen access
dc.subjectHIV-1es
dc.subjectDrug resistancees
dc.subjectTransmissiones
dc.subjectAntiretroviral therapyes
dc.subjectEuropees
dc.subjectBenzoxazinases
dc.subjectIntervalos de confianzaes
dc.subjectResistencia a medicamentoses
dc.subjectEuropa (Continente)es
dc.subjectInfecciones por VIHes
dc.subjectMutaciónes
dc.subjectPrevalenciaes
dc.subjectInhibidores de proteasases
dc.subjectSalud públicaes
dc.subjectInhibidores de la transcriptasa inversaes
dc.subjectRilpivirinaes
dc.subjectEncuestas y Cuestionarioses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazineses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervalses
dc.subject.meshMedical Subject Headings::Geographicals::Geographic Locations::Europees
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infectionses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutationes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalencees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitorses
dc.subject.meshMedical Subject Headings::Disciplines and Occupations::Health Occupations::Medicine::Public Healthes
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistancees
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitorses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirinees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaireses
dc.titleTransmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Hofstra_TransmisionOfHIVDrugResistance.pdf
Size:
422.12 KB
Format:
Adobe Portable Document Format
Description:
Artículo publicado
No Thumbnail Available
Name:
Hofstra_TransmisionOfHIVDrugResistanceSuppData.odt
Size:
18.8 KB
Format:
OpenDocument Text
Description:
Archivo complementario